We are live on ! Find out more
HBIO icon

Harvard Bioscience
HBIO

87 hedge funds and large institutions have $82.3M invested in Harvard Bioscience in 2020 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 32 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 6

167% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 12

46% more capital invested

Capital invested by funds: $56.4M → $82.3M (+$26M)

36% more funds holding

Funds holding: 64 → 87 (+23)

0.54% more ownership

Funds ownership: 6.38% → 6.92% (+0.54%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
87
Holders Change
+23
Holders Change %
+35.94%
% of All Funds
1.78%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
30
Increased
32
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4.44M
2
PAIM
Punch & Associates Investment Management
Minnesota
+$2.73M
3
ACM
Archon Capital Management
Washington
+$2.2M
4
PCM
Portolan Capital Management
Massachusetts
+$1.56M
5
HIM
Hillsdale Investment Management
Ontario, Canada
+$1.11M

Top Sellers

Rank Fund Capital Flow
1
ECM
Engine Capital Management
New York
-$10.1M
2
HP
Harvey Partners
New York
-$2.38M
3
Millennium Management
Millennium Management
New York
-$1.31M
4
ICM
Invenomic Capital Management
Massachusetts
-$1.09M
5
GIM
Granahan Investment Management
Massachusetts
-$304K
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
76
Legal & General Group
United Kingdom
$15K +$12.9K +478 New
Bank of Montreal
77
Bank of Montreal
Ontario, Canada
$11K +$8.24K +306 New
AIP
78
Ameritas Investment Partners
Nebraska
$10K +$8.97K +333 New
EARNEST Partners
79
EARNEST Partners
Georgia
$8K – – –
Rockefeller Capital Management
80
Rockefeller Capital Management
New York
$6K – – –
BNP Paribas Financial Markets
81
BNP Paribas Financial Markets
France
$4.38K +$3.72K +138 +4,600%
Royal Bank of Canada
82
Royal Bank of Canada
Ontario, Canada
$3K – – –
Osaic Holdings
83
Osaic Holdings
Arizona
$2K – – –
TFS
84
TrustCore Financial Services
Tennessee
$2K – – –
TFGT
85
TS Financial Group (TSFG)
Illinois
$1K – – –
ICM
86
Invenomic Capital Management
Massachusetts
– -$1.09M -49,156 Closed
FM
87
Fondren Management
Texas
– -$221K -10,000 Closed
Squarepoint
88
Squarepoint
New York
– -$43K -1,950 Closed
FDCDDQ
89
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$36.1K -1,614 Closed
WPC
90
White Pine Capital
Minnesota
– -$28K -1,270 Closed
Victory Capital Management
91
Victory Capital Management
Texas
– -$28K -1,226 Closed
1 2 3
4

HBIO Hedge Fund Activity: Q2 2020 in Review

87 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2020, worth a combined $82.3M — up 46% from $56.4M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new HBIO positions and 6 closed out — a net gain of 24 holders — while 32 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $4.44M. The largest seller was Engine Capital Management, cutting an estimated $10.1M.

  • 87 institutional investors held Harvard Bioscience (HBIO) as of Q2 2020, up from 64 in Q1 2020.
  • Funds reported $82.3M of Harvard Bioscience stock for Q2 2020, up 46% quarter-over-quarter.
  • 30 funds opened new Harvard Bioscience positions in Q2 2020 and 6 closed out, a net change of +24 holders.
  • The largest Harvard Bioscience buyer in Q2 2020 was BlackRock, an estimated $4.44M added.
  • The largest Harvard Bioscience seller in Q2 2020 was Engine Capital Management, an estimated $10.1M sold.

Based on aggregated 13F filings for Q2 2020.